The first-in-class p53 reactivator, PC14586, induced a response in approximately 1 of 4 patients with advanced solid tumors harboring p53 Y220C mutations and showcased an acceptable safety profile consisting primarily of grade 1 and 2 events.
Pipeline Report | Pipeline Report: July 2022
Pipeline Report: July 2022
Articles
Low-Dose Belantamab Mafodotin/Nirogacestat Demonstrates Encouraging Clinical Activity in R/R Myeloma
Nirogacestat plus belantamab mafodotin induced promising responses with manageable safety for patients with relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5